Shattuck Labs, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Shattuck Labs completed a $86.2M underwritten public offering and realized $57.1M from warrant exercises (July 2026), boosting cash/investments to $208.3M as of June 30, 2026 versus $50.5M a year prior. The company reports positive Phase 1 data for lead candidate SL-325 (DR3 blocking antibody) showing favorable safety, best-in-mechanism immunogenicity (3.7% antidrug antibodies), and durable blockade supporting quarterly dosing; Phase 2b trial (RECEPTIVE-CD1) in Crohn's disease initiates Q3 2026 with data expected H1 2028. SL-846 (DR3 × IL-23R bispecific) enters Phase 1 in 2027. Runway extends to 2029.
Why this rating
Capital raise ($143.3M) is 6.3× company market cap ($22.8M), materially extending runway. Phase 1 success de-risks lead program; Phase 2b initiation on track. Solvent through 2029 with clinical milestones.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.